|
| Tuesday, April 17, 2018 |
|
|
Jacobson Pharma Ranked No. 1 in "Hong Kong Best Small-Cap Company" in the "Asia's Best Companies Poll 2018" by FinanceAsia |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, is pleased to announce that Jacobson Pharma ranked no.1 in the category of Hong Kong Best Small-Cap Company in the "Asia's Best Companies Poll 2018" conducted by FinanceAsia, an authoritative financial magazine in Asia. more info >> |
|
| Wednesday, December 20, 2017 |
|
|
Jacobson Pharma Enters Agreements with Shanghai Henlius Biotech Inc. To Tap Biologics Market |
| Jacobson Pharma Corporation Limited today announced that through its wholly-owned subsidiaries, Jacobson Medical (Hong Kong) Limited and Joyful Ascent Limited, it has entered into a Licensing Framework Agreement and a Capital Increase Agreement with a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. namely, Shanghai Henlius Biotech Inc., a technological leader in research and development of biosimilar antibody drugs in China. more info >> |
|
|
雅各臣科研制药与上海复宏汉霖订立协议 进军生物制剂市场 |
| 从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业－雅各臣科研制药有限公司（「雅各臣集团」或「集团」；股份代号：2633）今天公布透过其全资附属公司雅各臣药业（香港）有限公司（「雅各臣药业」）及Joyful Ascent Limited（「认购方」） more info >> |
|
|
雅各臣科研製藥與上海復宏漢霖訂立協議 進軍生物製劑市場 |
| 從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業－雅各臣科研製藥有限公司（「雅各臣集團」或「集團」；股份代號：2633）今天公佈透過其全資附屬公司雅各臣藥業（香港）有限公司（「雅各臣藥業」）及Joyful Ascent Limited（「認購方」） more info >> |
|
|
Jacobson Pharma Enters Agreements with Shanghai Henlius Biotech Inc. To Tap Biologics Market |
| Jacobson Pharma Corporation Limited ("Jacobson Group" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines more info >> |
|
| Wednesday, November 22, 2017 |
|
|
雅各臣公布二零一八财年中期业绩 |
| 从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业─雅各臣科研制药有限公司（「雅各臣」或「公司」；股份代号：2633）今天公布公司及附属公司（统称「集团」）截至二零一七年九月三十日止六个月（「报告期」）的未经审核中期业绩。 more info >> |
|
|
雅各臣公佈二零一八財年中期業績 |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業─雅各臣科研製藥有限公司（「雅各臣」或「公司」；股份代號：2633）今天公佈公司及附屬公司（統稱「集團」）截至二零一七年九月三十日止六個月（「報告期」）的未經審核中期業績。
more info >> |
|
|
Jacobson Pharma Announces FY2018 Interim Results |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced its unaudited interim results of the Company and its subsidiaries (collectively the "Group") for the six months ended 30 September 2017 (the "Reporting Period"). more info >> |
|
| Tuesday, October 3, 2017 |
|
|
雅各臣完成发行本金总额为5亿港元的可换股票据予Dragons 615 Limited及HH InRe JP, Ltd. |
| 从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业─雅各臣科研制药有限公司（「雅各臣」或「集团」；股份代号：2633）欣然宣布已完成发行本金总额为5亿港元的可换股票据予两名认购人 more info >> |
|
|
雅各臣完成發行本金總額為5億港元的可換股票據予Dragons 615 Limited及HH InRe JP, Ltd. |
| 從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業─雅各臣科研製藥有限公司（「雅各臣」或「集團」；股份代號：2633）欣然宣佈已完成發行本金總額為5億港元的可換股票據予兩名認購人 more info >> |
|
|
|
|
